Teva Pharmaceutical Industries Ltd.'s new CSO and president of global R&D, Michael Hayden, plans to break down the silos housing generics and branded R&D with the aim of improving both businesses while better serving a global patient population.

He also has designs on increasing in-house discovery and personalized medicines efforts, and on opening up the organization to more innovative partnering.